REFERENCES
1. Roffi M., Patrono C., Collet J.P., et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37 (3): 267-315.
2. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013; 61 (4): e78-140.
3. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014; 64 (24): e139-228.
4. Authors/Task Force Members; Steg G., James S.K., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eu Heart J. 2012; 33 (20): 2569-19.
5. Ibanez B., James S., Agewall S., et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39 (2): 119-77.
6. Freemantle N., Cleland J., Young P, Mason J., Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318 (7200): 1730-7.
7. Chatterjee S., Biondi-Zoccai G., Abbate A., et al. Benefits of beta-blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013; 346 (1): f55.
8. Lee Y.H., Park J.S., Tahk S.J., et al. Beta-blocker therapy in the era of primary percutaneous intervention for ST elevation myocardial infarction. Cardiology. 2015; 132 (2): 91-100.
9. Puymirat E., Riant E., Aissoui N., et al. Beta-blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016; 354: i4801.
10. Ozasa N., Morimoto T., Bao B., et al. Beta-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol. 2013; 168 (2): 774 - 9.
11. Bangalore S., Makani H., Radford M., et al. Clinical outcomes with в-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014; 127 (10): 939-53.
12. Hori M., Sasayama S., Kitabatake A., et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004; 147 (2): 324-30.
13. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/ AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124 (23): e574-651.
14. Smith S.C. Jr, Benjamin E.J., Bonow R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation. 2011; 124 (22): 2458-73.
15. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. Eur Heart J. 2012; 33 (20): 2551-67.
16. Jneid H., Anderson J.L., Wright R.S., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2012; 60 (7): 645-81.
17. Dondo T.B., Hall M., West R.M., et al. Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017; 69 (22): 2710-20.
18. Huang B.T., Huang F.Y., Zuo Z.L., et al. Meta-analysis of relation between oral в-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol. 2015; 115 (11): 1529-38.
19. Li C., Sun Y., Shen X., et al. Relationship between beta-blocker therapy at discharge and clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Am Heart Assoc. 2016; 5 (11): e004190.
20. Yang J.H., Hahn J.Y., Song Y.B., et al. Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2014; 7 (6): 592-601.
21. Nakatani D., Sakata Y., Suna S., et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol. 2013; 111 (4): 457-64.
22. Bramlage P., Messer C., Bitterlich N., et al. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart. 2010; 96 (8): 604-9.